Gefitinib in Treating Patients With Advanced Unresectable Hepatocellular Carcinoma (Liver Cancer)
Status:
Completed
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
Phase II trial to study the effectiveness of gefitinib in treating patients who have advanced
unresectable hepatocellular carcinoma (liver cancer). Gefitinib may stop the growth of tumor
cells by blocking the enzymes necessary for their growth